Statin therapy and hemodialysis vascular access--were we bringing a knife to a gunfight and were hoping to win?

Abstract

Vascular access dysfunction is a major contributor to end stage renal disease patient morbidity, and the cost of maintaining it is staggering. Any intervention able to improve the vascular access maturation rate and/or patency would be significant progress. Based on the anti-inflammatory and vascular beneficial effects demonstrated in non-end stage renal disease patients, we were hoping that statin use might provide the much needed improvement in the hemodialysis vascular access outcome. The reality proved disappointing. The statins failed to improve every aspect of hemodialysis vascular access studied. The present editorial discusses the current data regarding the effect of statins on vascular access and attempts to explain their lack of success.

• Authors: Marius C Florescu, Nathan Birch
• Journal: Seminars in dialysis (Semin Dial) 2012 Nov-Dec Vol. 25 Issue 6 Pg. 700-2 ISSN: 1525-139X [Electronic] United States
• PMID: 22428869 (Publication Type: Journal Article)
• Copyright: © 2012 Wiley Periodicals, Inc.

Chemical References

• Hydroxymethylglutaryl-CoA Reductase Inhibitors

Topics

• Arteriovenous Shunt, Surgical
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (pharmacology, therapeutic use)
• Kidney Failure, Chronic (therapy)
• Renal Dialysis